Key result
Elevated RVSP on echocardiography is linked to greater comorbidity burden and increased hospitalizations.
Why the study?
The clinical significance of elevated RVSP on routine echocardiography is underappreciated, and the recent change lowering the hemodynamic threshold for PH from mean pulmonary arterial pressure >= 25 mm Hg to > 20 mm Hg further clouds the picture.
Does mildly to severely elevated right ventricular systolic pressure (RVSP ≥ 30 mm Hg) on routine echocardiography correlate with adverse clinical outcomes, higher comorbidity burden, and clinical recognition of pulmonary hypertension compared to RVSP < 30 mm Hg?
Cohort (n=9,291)
No
Does mildly to severely elevated right ventricular systolic pressure (RVSP ≥ 30 mm Hg) on routine echocardiography correlate with adverse clinical outcomes, higher comorbidity burden, and clinical recognition of pulmonary hypertension compared to RVSP < 30 mm Hg?
Answers are grounded in this paper and cite their sources.
Even mild-to-moderate RVSP elevation (30–40 mm Hg) on routine echocardiography—corresponding to the updated mPAP > 20 mm Hg definition of pulmonary hypertension—is highly prevalent (22.0%) and associated with increased comorbidity burden and hospitalizations, yet remains rarely diagnosed or investigated.
Background Although detection of elevated right ventricular systolic pressure (RVSP) on routine echocardiography is common, its clinical significance is underappreciated. The recent change in the hemodynamic definition of pulmonary hypertension (PH) lowering the threshold from mean pulmonary arterial pressure ≥ 25 mm Hg to > 20 mm Hg further clouds the picture. Methods A retrospective cohort study was performed on residents of the South East Local Health Integration Network (population 495,000), Ontario, Canada, who underwent transthoracic echocardiography at the Kingston Health Sciences Centre between February 19, 2013, and December 31, 2016. The index echocardiography from 9291 unique patients was obtained. Results A total of 2049 patients (22.1%) had an RVSP ≥ 40 mm Hg, 2040 patients (22.0%) had an RVSP ≥ 30 and < 40 mm Hg, but only 284 patients (3.1%) had a clinical diagnosis of PH. Although patients with an RVSP ≥ 40 mm Hg had the highest Charlson Comorbidity Index (CCI) (1.81 ± 0.05) and number of hospitalizations 1 year before the echocardiography (1.24 ± 0.03), patients with RVSP between 30 and 40 mm Hg also had significantly higher CCI (1.19 ± 0.04) and hospitalization (0.87 ± 0.03) compared with the CCI (0.84 ± 0.03) and hospitalization (0.65 ± 0.02) of patients with RVSP < 30 mm Hg ( P < 0.0001). Conclusion Despite the finding that an elevated RVSP ≥ 30 mm Hg is common and predicts adverse outcomes, most patients with elevated RVSP are not reported as having PH or investigated. The significance of the elevated RVSP is underappreciated.
No takes yet. Share an insight, caveat, or question.
Xiong et al. (2020) conducted a cohort in Suspected or echocardiographically detected pulmonary hypertension (elevated RVSP) (n=9,291). Elevated right ventricular systolic pressure (RVSP >= 30 and < 40 mm Hg, or RVSP >= 40 mm Hg) on transthoracic echocardiography vs. Normal right ventricular systolic pressure (RVSP < 30 mm Hg) or no measurable RVSP was evaluated on Charlson Comorbidity Index (CCI) and number of hospitalizations 1 year before and 1 year after index echocardiography (p=<0.0001). Elevated RVSP (30-40 mm Hg and >=40 mm Hg) on echocardiography was present in 44.1% of patients and predicted higher comorbidity burden and hospitalizations.
Synapse has enriched 10 related papers. Consider them for comparative context: